To develop a vaccine that targets individualized neoantigen in NSCLC patients with EGFR mutations who do respond to ICIs, we performed a retrospective analysis of 1862 Chinese NSCLC tumor tissues matched with normal tissue samples which were previously profiled using our 1021-gene panel. Here, EGFR is linked to neoplasm.